{'fraction_non_alphanumeric': 0.06970128022759602, 'fraction_numerical': 0.04694167852062589, 'mean_word_length': 4.101449275362318, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Plasma methotrexate concentrations in urothelial cancer chemotherapy].

The plasma methotrexate (MTX) concentration was measured during 50 courses of chemotherapy on 26 urothelial cancer patients. A dose of 300 mg/body MTX was infused within 2 hours and plasma concentrations were measured at the scheduled times. Plasma level at the end of infusion was (2.3 +/- 0.8) x 10(-5) M/L, (2.9 +/- 1.9) x 10(-5) M/L at the 6th-hour, and (1.9 +/- 1.8) x 10(-7) M/L at the 24th-hour after the infusion. The plasma MTX concentration values were inversely correlated with creatinin clearance. In 6 cases of Kock pouch bladder, clean intermittent self catheterization of urine caused no meaningful increase of MTX.